Voyager Therapeutics (VYGR) Total Liabilities (2014 - 2026)
Voyager Therapeutics (VYGR) posted Total Liabilities of $45.7 million for Q1 2026, down 18.76% sequentially from $56.2 million in Q4 2025, and down 43.31% YoY from $80.5 million in Q1 2025.
Voyager Therapeutics (VYGR) Total Liabilities (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Total Liabilities for 13 years, with the latest figure at $45.7 million in Q1 2026.
- Quarterly Total Liabilities fell 43.31% year-over-year to $45.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.7 million (down 43.31% YoY) and the FY2025 annual result came in at $56.2 million, down 39.76% from the prior year.
- Total Liabilities eased to $45.7 million in Q1 2026 per VYGR's latest filing, from $56.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $148.3 million in Q1 2022 and troughed at $45.7 million in Q1 2026.
- A 5-year average of $99.8 million and a median of $100.8 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities soared 46.05% in 2022, then slumped 43.31% in 2026.
- Over 5 years, Total Liabilities stood at $100.3 million in 2022, then increased by 14.58% to $115.0 million in 2023, then decreased by 18.85% to $93.3 million in 2024, then slumped by 39.76% to $56.2 million in 2025, then fell by 18.76% to $45.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $45.7 million, $56.2 million, and $68.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 43.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.38 Mn |
| Mar 31, 2026 | 45.66 Mn |
| Dec 31, 2025 | 56.20 Mn |
| Sep 30, 2025 | 68.49 Mn |
| Jun 30, 2025 | 78.16 Mn |
| Mar 31, 2025 | 80.54 Mn |
| Dec 31, 2024 | 93.29 Mn |
| Sep 30, 2024 | 95.73 Mn |
| Jun 30, 2024 | 100.81 Mn |
| Mar 31, 2024 | 128.71 Mn |
| Dec 31, 2023 | 114.96 Mn |
| Sep 30, 2023 | 118.43 Mn |
| Jun 30, 2023 | 116.51 Mn |
| Mar 31, 2023 | 119.33 Mn |
| Dec 31, 2022 | 100.34 Mn |
| Sep 30, 2022 | 102.66 Mn |
| Jun 30, 2022 | 128.55 Mn |
| Mar 31, 2022 | 148.25 Mn |
| Dec 31, 2021 | 98.80 Mn |
| Sep 30, 2021 | 97.35 Mn |